DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR CYTOSAR-U

« Back to Dashboard

All Clinical Trials for Cytosar-u

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00002833	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	National Cancer Institute (NCI)	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002833	Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia	Completed	M.D. Anderson Cancer Center	Phase 2	1994-10-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Colony stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation plus filgrastim in treating patients who have acute or chronic myelogenous leukemia.
NCT00002835	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	National Cancer Institute (NCI)	Phase 3	1995-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
NCT00002835	Combination Chemotherapy in Treating Patients With Lymphoma	Completed	M.D. Anderson Cancer Center	Phase 3	1995-07-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. PURPOSE: Randomized phase III trial to compare the effectiveness of two regimens of combination chemotherapy in treating patients who have intermediate-grade or immunoblastic lymphoma.
NCT00004263	Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	National Cancer Institute (NCI)	Phase 1	1999-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. UCN-01 may make cancer cells more sensitive to cytarabine. PURPOSE: Phase I trial to study the effectiveness of cytarabine and UCN-01 in treating patients who have refractory or relapsed acute myelogenous leukemia or myelodysplastic syndrome.
NCT00004263	Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic Syndrome	Completed	M.D. Anderson Cancer Center	Phase 1	1999-12-01	RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. UCN-01 may make cancer cells more sensitive to cytarabine. PURPOSE: Phase I trial to study the effectiveness of cytarabine and UCN-01 in treating patients who have refractory or relapsed acute myelogenous leukemia or myelodysplastic syndrome.
NCT00067028	Clofarabine Combinations in Relapsed/Refractory AML, MDS and Myeloid Blast Phase CML	Completed	Genzyme, a Sanofi Company	Phase 2	2003-12-01	The goal of this clinical research study is to find the best safe dose for 2 different drug combinations. For this purpose, participants will either receive the combination of clofarabine plus idarubicin or clofarabine plus idarubicin and ara-C. Once the best safe dose for these drug combinations are found, the next goal is to compare the drug combinations clofarabine/idarubicin/ara-C, clofarabine/ara-C, and clofarabine/idarubicin in the treatment of patients with Acute Myeloid Leukemia, high-grade MDS, or myeloid blast phase of Chronic Myeloid Leukemia who have relapsed following their initial therapy. In the current extension part of the study, you will only receive the clofarabine/idarubicin/ara-C combination. The activity and the safety of this treatment will be studied.

Clinical Trial Conditions for Cytosar-u

Condition Name

Condition Name for Cytosar-u
Intervention	Trials
Acute Myeloid Leukemia	14
Leukemia	11
Refractory Acute Myeloid Leukemia	8
Recurrent Acute Myeloid Leukemia	7

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Cytosar-u
Intervention	Trials
Leukemia	44
Leukemia, Myeloid	29
Leukemia, Myeloid, Acute	28
Myelodysplastic Syndromes	16

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Cytosar-u

Trials by Country

Trials by Country for Cytosar-u
Location	Trials
United States	46
Italy	24
China	1
Iran, Islamic Republic of	1

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Cytosar-u
Location	Trials
Texas	30
Washington	4
Ohio	2
California	2
Pennsylvania	1

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Cytosar-u

Clinical Trial Phase

Clinical Trial Phase for Cytosar-u
Clinical Trial Phase	Trials
Phase 3	5
Phase 2/Phase 3	3
Phase 2	26

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Cytosar-u
Clinical Trial Phase	Trials
Not yet recruiting	29
Completed	14
Recruiting	13

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Cytosar-u

Sponsor Name

Sponsor Name for Cytosar-u
Sponsor	Trials
National Cancer Institute (NCI)	34
M.D. Anderson Cancer Center	30
Fred Hutchinson Cancer Research Center	3

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Cytosar-u
Sponsor	Trials
Other	51
NIH	34
Industry	20

Export unavailable in trial.
Subscribe for complete access.